Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Novartis AG is acquiring Avidity Biosciences in an all-cash deal valued at $12 billion, or $72 per share, representing a 46% premium to Avidity's recent closing price. This strategic acquisition aims to significantly enhance Novartis's neuroscience and rare disease portfolio through Avidity's late-stage AOC platform, which includes therapies for Duchenne muscular dystrophy and myotonic dystrophy type 1. As part of the transaction, Avidity will spin off its early-stage precision cardiology programs into a new publicly traded company, with current shareholders receiving equity in this new entity alongside the cash payment. H.C. Wainwright analysts have since downgraded Avidity to Neutral, matching the $72 offer and indicating a low probability of a higher bid.

Analysis

Novartis AG has announced an all-cash acquisition of Avidity Biosciences (RNA) for $12 billion, or $72 per share, representing a substantial 46% premium to RNA's Oct. 24 closing price and 62% to its 30-day VWAP. This significant biotech buyout has led to RNA shares trading higher by 42.41% to $70.00, reflecting strong market approval for the offer.

The acquisition strategically bolsters Novartis's neuroscience and rare disease portfolio, leveraging Avidity's late-stage AOC pipeline, which includes promising therapies like del-zota for Duchenne muscular dystrophy and del-desiran for myotonic dystrophy type 1. This move underscores Novartis's commitment to expanding its therapeutic reach in high-growth, specialized areas.

A unique aspect of the deal involves Avidity spinning out its early-stage precision cardiology programs into a new publicly traded entity (SpinCo), funded with $270 million in cash, with existing RNA shareholders receiving equity in this new company. H.C. Wainwright analysts downgraded RNA to Neutral with a $72 price target, matching the offer, and do not anticipate a competing bid, suggesting the deal's finality.

Despite a Q2 loss of $1.21 per share, missing estimates, Avidity demonstrated robust sales growth, with revenue surging 88% year-over-year to $3.85 million, significantly exceeding the $1.46 million consensus. This strong top-line performance, coupled with the advanced pipeline, likely contributed to the attractive valuation and strategic interest from Novartis.

Key Decisions for Investors

• Current RNA shareholders should consider tendering shares for the $72 cash offer, as analysts expect no competing bids, while also evaluating the intrinsic value of the forthcoming SpinCo equity.
• Novartis investors should assess the strategic implications of this significant acquisition on NVS's neuroscience pipeline and long-term R&D focus, considering the substantial premium paid.
• Monitor the progress and market positioning of the new SpinCo, as its early-stage cardiology programs represent a separate, potentially high-growth investment opportunity for those receiving its shares.